Opendata, web and dolomites

EuroNeurotrophin SIGNED

A European training network for the discovery of neurotrophins small molecule mimetics as candidate therapeutic agents for neurodegeneration and neuroinflammation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EuroNeurotrophin project word cloud

Explore the words cloud of the EuroNeurotrophin project. It provides you a very rough idea of what is the project "EuroNeurotrophin" about.

conduct    forth    euroneurotrophin    translation    14    profiles    neurodegenerative    possess    pathogenesis    diseases    preclinical    small    societies    nd    seminal    actions    neurons    deep    drugs    market    discovery    collaborations    successful    interrogate    fail    exists    poor    clinical    collaborative    ad    skills    specialists    pharmacokinetic    survival    single    of    neuroprotection    nhrf    tissue    tackle    skilled    translate    drug    network    stage    prohibitive    molecule    stability    12    probes    complementary    render    first    pd    accelerate    mimetics    groups    idea    comprehend    treatments    therapies    builds    ms    academic    therapeutic    molecular    designed    enriched    motivated    collectively    shown    molecules    mnd    biological    neurotrophins    limitation    neurotrophin    doctoral    private    function    worldwide    beneficiaries    demonstrated    consists    point    als    cure    patented    companies    penetration    candidate    emphasise    expertise    training    neurogenesis   

Project "EuroNeurotrophin" data sheet

The following table provides information about the project.

Coordinator
ETHNIKO IDRYMA EREVNON 

Organization address
address: VAS KONSTANTINOU 48
city: ATHINA
postcode: 11635
website: www.eie.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Total cost 3˙555˙758 €
 EC max contribution 3˙555˙758 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ETHNIKO IDRYMA EREVNON EL (ATHINA) coordinator 484˙773.00
2    AvantiCell Science Ltd UK (AYR) participant 546˙575.00
3    HITS GGMBH DE (HEIDELBERG) participant 498˙432.00
4    IDRYMA TECHNOLOGIAS KAI EREVNAS EL (IRAKLEIO) participant 484˙773.00
5    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 273˙287.00
6    UNIVERSITE DE CAEN NORMANDIE FR (CAEN CEDEX 5) participant 262˙875.00
7    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 258˙061.00
8    STICHTING VU NL (AMSTERDAM) participant 255˙374.00
9    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 249˙216.00
10    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 242˙386.00
11    ACCELOPMENT AG CH (ZUERICH) partner 0.00
12    Innovative Technologies in Biological Systems ES (Derio) partner 0.00
13    Novartis (Ελλάς) Α.Ε.Β.Ε. EL (Metamorphosis) partner 0.00
14    PANEPISTIMIO KRITIS EL (RETHIMNO) partner 0.00
15    Peakdale Molecular Limited UK (Chapel-en-le-Frith) partner 0.00
16    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) partner 0.00
17    Ventac A/S DK (Hoersholm) partner 0.00

Map

 Project objective

Neurodegenerative diseases (ND) like AD, PD, MS and ALS/MND are on the rise in developed societies worldwide. Currently, there exists no cure for any ND, and most of the available drugs fail to tackle ND pathogenesis. Preclinical studies point to the therapeutic potential of neurotrophins, which have been shown to control a number of aspects of survival, development and function of neurons. However, the poor pharmacokinetic properties of neurotrophins render their use as drugs prohibitive. The key idea behind this project is to address this limitation by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions. We are motivated by seminal (patented) results of beneficiaries NHRF and FORTH, who recently demonstrated promising effects of small neurotrophin mimetics in neuroprotection and neurogenesis. EuroNeurotrophin will be the first European consortium to study small molecule neurotrophin mimetics in depth, use them as molecular probes to interrogate neurotrophins, and emphasise their clinical translation. This approach requires highly skilled researchers that have a deep understanding of neurotrophins, comprehend all steps of drug discovery and development for ND, and possess the necessary skills to translate results into novel therapies. The network has been designed to address the need for the development of new ND treatments through the collaborative training of 14 early-stage researchers. It builds on previous successful collaborations enriched with key specialists, and consists of 12 leading European research groups and 6 private companies of complementary expertise covering all steps of drug discovery and development. Collectively we will (a) conduct a unique training programme that could not be achieved by doctoral training within a single academic institution and (b) accelerate the translation of identified drug candidate molecules into the market.

 Publications

year authors and title journal last update
List of publications.
2020 Athanasios Ziogas, Tomoki Maekawa, Johannes R. Wiessner, Thi Trang Le, David Sprott, Maria Troullinaki, Ales Neuwirth, Vasiliki Anastasopoulou, Sylvia Grossklaus, Kyoung-Jin Chung, Markus Sperandio, Triantafyllos Chavakis, George Hajishengallis, Vasileia Ismini Alexaki
DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1
published pages: 1214-1224, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1900746
The Journal of Immunology 204/5 2020-03-11
2019 Canelif Yilmaz, Kanelina Karali, Georgia Fodelianaki, Achille Gravanis, Triantafyllos Chavakis, Ioannis Charalampopoulos, Vasileia Ismini Alexaki
Neurosteroids as regulators of neuroinflammation
published pages: 100788, ISSN: 0091-3022, DOI: 10.1016/j.yfrne.2019.100788
Frontiers in Neuroendocrinology 55 2020-03-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURONEUROTROPHIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EURONEUROTROPHIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

HEARTLAND (2019)

Health, Environment, Agriculture, Rural development: Training network for LAND management

Read More  

ENHAnCE (2020)

European training Network in intelligent prognostics and Health mAnagement in Composite structurEs

Read More  

PoLiMeR (2018)

Polymers in the Liver: Metabolism and Regulation

Read More